Consequently, the activity of RIPK2 has been implicated in a subset of systemic granulomatous inflammatory diseases (Jun et al, 2013) and, in particular, ablation of Ripk2 or inhibition of RIPK2 by small‐molecule kinase inhibitors showed benefits in mouse models of multiple sclerosis (Shaw et al, 2011; Nachbur et al, 2015) and Crohn's disease‐like ileitis (Tigno‐Aranjuez et al, 2014), positioning RIPK2 as a new target against human inflammatory diseases. This evidence concerns the gene RIPK2 and Crohn ileitis.